Selank for Cognitive Enhancement: Anxiolytic Claims, Dosing & Evidence Quality

Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. It is a modified analog of the immunomodulatory peptide tuftsin (Thr-Lys-Pro-Arg) with an added Pro-Gly-Pro sequence to improve stability. Selank has been registered as an anxiolytic drug in Russia under the brand name Selank (0.15% nasal drops) and has a separate Russian registry entry as a nootropic. Understanding the evidence quality requires knowing that the majority of published research originates from Russian institutions and was not consistently registered in international clinical trial databases.

Claimed Mechanisms: Anxiolytic and Nootropic

Selank is proposed to exert anxiolytic effects through modulation of GABAergic neurotransmission (similar to benzodiazepines, but without direct GABA receptor agonism — possibly by affecting GABA metabolism), as well as through modulation of serotonin and dopamine turnover. Russian studies also report increases in brain-derived neurotrophic factor (BDNF) levels, which could underlie the claimed nootropic (memory-enhancing, focus-improving) properties.

Immunomodulatory activity — inherited from its tuftsin parent — includes stimulation of T-cell-mediated immunity and modulation of cytokine expression (reported increases in IL-6, IFN-γ in some studies, and decreases in inflammatory markers in others). The immunological effects are incompletely characterized and their relevance to cognitive or anxiolytic function is unclear.

Evidence Quality: The Russian Literature Problem

This is the most important section of this guide. The overwhelming majority of Selank publications — both preclinical and clinical — come from a small number of Russian research institutions, many with a direct institutional interest in the compound’s development. Key problems: (1) Many studies are published in Russian-language journals with limited international peer review; (2) clinical trials were often small (n = 20–60) and not randomized by modern standards; (3) trial registration and placebo control methodologies are not consistently reported; (4) independent replication outside Russia is essentially absent from the published record. This does not mean Selank is ineffective — but it means the evidence cannot be treated at the same level as, for example, the STEP-1 or SURMOUNT-1 trial data. Researchers should approach Selank’s claimed benefits with proportionately higher skepticism.

Intranasal Route and Bioavailability

Selank’s registered clinical form is a 0.15% nasal drop solution. The intranasal route allows direct access to the CNS via the olfactory epithelium, bypassing the blood-brain barrier for at least a portion of the delivered dose. This is pharmacologically significant: most peptides administered systemically have poor CNS penetration due to their hydrophilicity and size. Intranasal delivery concentrates the peptide at the nasal mucosa with direct neuronal access, which may explain why a small intranasal dose (typically 250–900 μg per administration) can produce CNS effects.

Subcutaneous administration is also used in research contexts, typically at doses of 250–500 μg per injection. The systemic bioavailability comparison between intranasal and SC routes for Selank has not been rigorously published.

Half-Life and Dosing Frequency

Selank has a reported half-life of approximately 2 minutes in plasma due to rapid enzymatic degradation by peptidases. This extremely short circulating half-life means Selank effects are likely mediated by receptor interactions that trigger downstream signaling cascades lasting beyond the peptide’s plasma presence, or by CNS-local actions after intranasal delivery where it is more protected from systemic peptidases. Russian clinical protocols have used Selank intranasally 2–3 times daily for 10–14 day courses.

Comparison to Anxiolytic Drug Classes

Unlike benzodiazepines, Selank is reported not to cause sedation, motor impairment, or physical dependence in Russian studies. Unlike SSRIs, it does not require weeks of loading to produce effect. These claimed properties, if validated by independent research, would represent a meaningful differentiation. However, the absence of regulatory-grade independent RCTs means these comparative claims cannot be verified against existing anxiolytic standards.

Regulatory Status

Selank is approved as a drug in Russia. It has no approved status in the United States, European Union, or most Western regulatory jurisdictions. It is not scheduled as a controlled substance in most countries, but it also lacks the regulatory review that would confirm safety and efficacy for international markets. Researchers outside Russia obtain Selank as a research compound from peptide vendors — quality verification via COA is essential. See /guides/reading-a-coa for COA guidance.